NCT01284192View on ClinicalTrials.gov

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

February 28, 2014

Study Completion Date

March 31, 2016

Conditions
Advanced MalignanciesPositive for Anaplastic Lymphoma KinasePositive for Proto-Oncogene Tyrosine-Protein Kinase ROSSolid TumorB-Cell Lymphoma
Interventions
DRUG

ASP3026

Tablet

Trial Locations (6)

48201

Site US2688, Detroit

60637

Site US11, Chicago

77030

Site US2492, Houston

78229

Site US1905, San Antonio

92868

Site US160, Orange

95817

Site US184, Sacramento

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY